3645 results for «617»
3645 results
Vascular access: femoral and radial
20 May 2026 – From EuroPCR 2026
This session explores vascular access techniques in interventional cardiology, emphasizing both femoral and radial approaches. It covers access-related bleeding and ischemic complications, safety and efficacy of distal radial programs, and innovations in sheath technology. Additional topics include post-procedural mobilization, management of radial artery recanalization, balloon fenestration...
Double face of DCB in clinical practice
20 May 2026 – From EuroPCR 2026
This session examines the dual aspects of drug-coated balloons (DCB) in clinical practice through diverse case studies. Topics include DCB use in left main STEMI, OCT-guided management of in-stent restenosis, expanding indications for complex PCI, and challenges such as DCB failure and decision-making between drug-eluting balloons...
Advanced mitral TEER strategies in complex clinical scenarios
20 May 2026 – From EuroPCR 2026
This session presents advanced strategies for mitral transcatheter edge-to-edge repair (TEER) in complex clinical settings. Through cases involving surgical ring dehiscence, acute mitral regurgitation, dextrocardia, congenital anomalies, severe annular calcifications, and creative procedural approaches, it explores the expanding role of TEER. The session provides guidance on...
Interventions for hypertension: latest developments
20 May 2026 – From EuroPCR 2026
This session reviews the latest developments in interventional treatments for hypertension, focusing on renal denervation (RDN) technologies and clinical outcomes. It includes comparative procedural data from global registries and studies, novel computational assessments, and applications in specific patient populations such as those with polycystic kidney disease...
Drug-coated balloon (DCB) technology: A pioneer’s view of the historical evolution and future directions
08 Jan 2025
In this article, Bruno Scheller explores advances in local drug delivery, from drug-coated balloons to novel antiproliferative agents. These innovations aim to reduce restenosis, minimize permanent implants, and pave the way for patient-specific coronary artery disease treatments.
Author
